STAT+: FDA backs proposals to entice pharma companies to test, make drugs domestically
Why it matters: The FDA's proposals aim to shift drug manufacturing and early-stage trials to the U.S. from China.
- FDA Commissioner Marty Makary believes "giant, big ideas" are necessary to combat China's dominance in early-stage drug development.
- The FDA proposes policies within the president’s budget to encourage domestic drug development and manufacturing.
- Proposed policies aim to simplify early-stage trials in the U.S. and give an edge to U.S.-based generics manufacturers.
- The Trump administration previously used tariffs and price-lowering deals to compel brand drugmakers to increase domestic manufacturing.
- STAT News also covers related industry news, including an FDA delay that forced a biotech to close and a Neurocrine deal, indicating broader impacts of regulatory actions on the biotech sector.
The FDA is proposing new policies within the president's budget to incentivize domestic drug development and manufacturing, aiming to counter China's lead in early-stage clinical trials. These proposals include making it easier to conduct early-stage trials in the U.S. and offering advantages to U.S.-based generics manufacturers, building on previous Trump administration efforts to bring drug manufacturing back home.
